Xilio Therapeutics (XLO) Cash from Investing Activities Growth (3y) (2024 - 2026)
Xilio Therapeutics (XLO) Cash from Investing Activities Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -48.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.44% |
| Dec 31, 2025 | 42.85% |
| Jun 30, 2025 | 19.58% |
| Mar 31, 2025 | 55.76% |
| Dec 31, 2024 | 74.87% |
| Sep 30, 2024 | 57.10% |